Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. / Hojbjerg, Johanne Andersen; Ebert, Eva Boysen Fynboe; Clement, Michelle Simone; Winther-Larsen, Anne; Meldgaard, Peter; Sorensen, Boe.

In: Lung Cancer, Vol. 135, 09.2019, p. 92-96.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{5d298b8f4d0b4f7992e0ab3c36f3df38,
title = "Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients",
abstract = "Objectives: MiR-30b, miR-30c, miR-221 and miR-222 are known to induce gefitinib resistance in lung cancer cell lines with activation of mutations in the epidermal growth factor receptor (EGFR). However, the role of these four microRNAs in tyrosine kinase inhibitor (TKI)-resistance in non-small cell lung cancer (NSCLC) patients is unknown. Thus, the aim of this study was to investigate the predictive value of miR-30b, miR-30c, miR-221 and miR-222 in plasma from EGFR-mutated lung cancer patients receiving erlotinib. Materials and methods: The cohort consisted of 29 EGFR-mutated lung cancer patients receiving erlotinib. Plasma levels of miR-30b, miR-30c, miR-221 and miR-222 were analyzed by qPCR from blood samples collected before treatment start. Plasma concentration of each microRNA was correlated to clinical outcome. Results: Plasma concentrations of miR-30b and miR-30c could be determined in all 29 patients. Low plasma concentrations of miR-30b and miR-30c showed significant correlation with superior progression-free survival (PFS) (miR-30b: HR = 0.303 [0.123–0.747], p < 0.05; miR-30c: HR = 0.264 [0.103–0.674], p < 0.05). Low plasma concentrations of miR-30c were also significantly correlated with superior overall survival (OS) (HR = 0.30 [0.094–0.954], p < 0.041). Conclusion: High plasma concentrations of miR-30b and miR-30c predicted shorter PFS and OS. This implies that miR-30b and miR-30c could have clinical potential as biomarkers in EGFR-mutated lung cancer patients.",
keywords = "Biomarkers, EGFR mutations, Intrinsic resistance, MicroRNA, NSCLC",
author = "Hojbjerg, {Johanne Andersen} and Ebert, {Eva Boysen Fynboe} and Clement, {Michelle Simone} and Anne Winther-Larsen and Peter Meldgaard and Boe Sorensen",
year = "2019",
month = "9",
doi = "10.1016/j.lungcan.2019.07.005",
language = "English",
volume = "135",
pages = "92--96",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd.",

}

RIS

TY - JOUR

T1 - Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients

AU - Hojbjerg, Johanne Andersen

AU - Ebert, Eva Boysen Fynboe

AU - Clement, Michelle Simone

AU - Winther-Larsen, Anne

AU - Meldgaard, Peter

AU - Sorensen, Boe

PY - 2019/9

Y1 - 2019/9

N2 - Objectives: MiR-30b, miR-30c, miR-221 and miR-222 are known to induce gefitinib resistance in lung cancer cell lines with activation of mutations in the epidermal growth factor receptor (EGFR). However, the role of these four microRNAs in tyrosine kinase inhibitor (TKI)-resistance in non-small cell lung cancer (NSCLC) patients is unknown. Thus, the aim of this study was to investigate the predictive value of miR-30b, miR-30c, miR-221 and miR-222 in plasma from EGFR-mutated lung cancer patients receiving erlotinib. Materials and methods: The cohort consisted of 29 EGFR-mutated lung cancer patients receiving erlotinib. Plasma levels of miR-30b, miR-30c, miR-221 and miR-222 were analyzed by qPCR from blood samples collected before treatment start. Plasma concentration of each microRNA was correlated to clinical outcome. Results: Plasma concentrations of miR-30b and miR-30c could be determined in all 29 patients. Low plasma concentrations of miR-30b and miR-30c showed significant correlation with superior progression-free survival (PFS) (miR-30b: HR = 0.303 [0.123–0.747], p < 0.05; miR-30c: HR = 0.264 [0.103–0.674], p < 0.05). Low plasma concentrations of miR-30c were also significantly correlated with superior overall survival (OS) (HR = 0.30 [0.094–0.954], p < 0.041). Conclusion: High plasma concentrations of miR-30b and miR-30c predicted shorter PFS and OS. This implies that miR-30b and miR-30c could have clinical potential as biomarkers in EGFR-mutated lung cancer patients.

AB - Objectives: MiR-30b, miR-30c, miR-221 and miR-222 are known to induce gefitinib resistance in lung cancer cell lines with activation of mutations in the epidermal growth factor receptor (EGFR). However, the role of these four microRNAs in tyrosine kinase inhibitor (TKI)-resistance in non-small cell lung cancer (NSCLC) patients is unknown. Thus, the aim of this study was to investigate the predictive value of miR-30b, miR-30c, miR-221 and miR-222 in plasma from EGFR-mutated lung cancer patients receiving erlotinib. Materials and methods: The cohort consisted of 29 EGFR-mutated lung cancer patients receiving erlotinib. Plasma levels of miR-30b, miR-30c, miR-221 and miR-222 were analyzed by qPCR from blood samples collected before treatment start. Plasma concentration of each microRNA was correlated to clinical outcome. Results: Plasma concentrations of miR-30b and miR-30c could be determined in all 29 patients. Low plasma concentrations of miR-30b and miR-30c showed significant correlation with superior progression-free survival (PFS) (miR-30b: HR = 0.303 [0.123–0.747], p < 0.05; miR-30c: HR = 0.264 [0.103–0.674], p < 0.05). Low plasma concentrations of miR-30c were also significantly correlated with superior overall survival (OS) (HR = 0.30 [0.094–0.954], p < 0.041). Conclusion: High plasma concentrations of miR-30b and miR-30c predicted shorter PFS and OS. This implies that miR-30b and miR-30c could have clinical potential as biomarkers in EGFR-mutated lung cancer patients.

KW - Biomarkers

KW - EGFR mutations

KW - Intrinsic resistance

KW - MicroRNA

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=85069609345&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2019.07.005

DO - 10.1016/j.lungcan.2019.07.005

M3 - Journal article

VL - 135

SP - 92

EP - 96

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -